RxDoctor Payments Data

Brooke Mantie, APRN

Family · Las Vegas, NVNPI 1558032532

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 105 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$737
  • Merck$318
  • Gilead$196
  • Janssen Products, LP$87
  • Hologic Sales And Service, LLC$75
  • Theratechnologies Inc.$71
  • plus $209 from 5 others

What the payments were for

  • Food & beverage$1,60695%
  • Education$875%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,693 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$8,443
Medicare patients
26
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine320$925,341
BiktarvyBictegrav/Emtricit/Tenofov Ala125$488,876
SerostimSomatropin15$220,776
RukobiaFostemsavir Tromethamine18$164,616
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf35$156,663
OdefseyEmtricitab/Rilpiviri/Tenof Ala40$142,241
JulucaDolutegravir/Rilpivirine26$90,523
TriumeqAbacavir/Dolutegravir/Lamivudi24$85,396
DescovyEmtricitabine/Tenofov Alafenam33$70,396
TivicayDolutegravir Sodium28$60,674
OzempicSemaglutide56$58,614
PrezcobixDarunavir/Cobicistat23$54,849
JardianceEmpagliflozin28$23,771
RexultiBrexpiprazole13$19,235
TrulicityDulaglutide11$16,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Rukobia, Juluca, Triumeq, Tivicay$737$1,326,551416 claims
GileadBiktarvy, Descovy$196$559,272158 claims
EMD Serono, Inc.Serostim$69$220,77615 claims
Janssen Products, LPSymtuza$87$156,66335 claims
Johnson & JohnsonPrezcobix$56$54,84923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →